Italian PACS firm plans entry into U.S.

Article

Italian PACS firm plans entry into U.S.An Italian PACS developer has filed a 510(k) application with the Food and Drug Administration in preparation for U.S. sales of its product line. The company, Program S.r.l. of Vicenza, has also signed a

Italian PACS firm plans entry into U.S.

An Italian PACS developer has filed a 510(k) application with the Food and Drug Administration in preparation for U.S. sales of its product line. The company, Program S.r.l. of Vicenza, has also signed a letter of intent with a U.S. company for exclusive distribution rights in the U.S. and Canada.

Program was established in 1994 and has a dominant share of the PACS market in Italy, where it installed its first beta site three years ago. Program's products are also marketed in Germany, Switzerland, and Austria, and the company recently signed on Duncan Hynd Associates (DHA) for distribution in the U.K. and Ireland.

Program's MedStation PACS line is based on the Windows NT operating system, and company representatives compare it to offerings from Rogan, Applicare, Cemax-Icon, and CompuRad. One differentiating feature of MedStation, however, is its ability to conduct maximum intensity projection (MIP) image-fusion display, in which an image from one modality, such as CT, is overlaid on that from another, like MRI. The technique is often used for applications such as radiation treatment planning.

In addition to filing the 510(k) application for MedStation last month, Program is in discussions with Service Support Group (SSG) of Seattle for exclusive North American distribution rights. SSG is an equipment service and asset management company that is interested in entering the market for healthcare information technology. Program hopes to have clearance for MedStation by this year's Radiological Society of North America meeting.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.